Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
- DOI
- 10.1136/bmjopen-2021-056159
- Published
- 2022-03
- Container
- BMJ Open
- Publisher
- BMJ
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/bmjopen-2021-056159,
title = {Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study},
author = {Neeta B Amin and Amanda Darekar and Quentin M Anstee and Vincent Wai-Sun Wong and Frank Tacke and Manoli Vourvahis and Douglas S Lee and Michael Charlton and Naim Alkhouri and Atsushi Nakajima and Carla Yunis},
year = {2022},
journal = {BMJ Open},
doi = {10.1136/bmjopen-2021-056159},
url = {https://doi.org/10.1136/bmjopen-2021-056159}
}RIS
TY - JOUR TI - Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study AU - Neeta B Amin AU - Amanda Darekar AU - Quentin M Anstee AU - Vincent Wai-Sun Wong AU - Frank Tacke AU - Manoli Vourvahis AU - Douglas S Lee AU - Michael Charlton AU - Naim Alkhouri AU - Atsushi Nakajima AU - Carla Yunis PY - 2022 JO - BMJ Open DO - 10.1136/bmjopen-2021-056159 UR - https://doi.org/10.1136/bmjopen-2021-056159 ER -
APA
Amin, N. B., Darekar, A., Anstee, Q. M., Wong, V. W., Tacke, F., Vourvahis, M., Lee, D. S., Charlton, M., Alkhouri, N., Nakajima, A., & Yunis, C. (2022). Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open. https://doi.org/10.1136/bmjopen-2021-056159
Source records
- crossref · retrieved 2026-09-27T13:19:26.408Z